.Attribute Medication, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- medication conjugate (ADC) tisotumab vedotin resulted in enhanced progression-free and also general survival, resulting in FDA commendation and a new treatment possibility for people.